<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugResultsOutput hits="20" offset="0" totalResults="1015"><SearchResults><Drug id="99954" name="small molecule therapeutic (oral/tablet, rheumatoid arthritis), Institute of Materia Medica/Beijing Union Pharmaceutical Factory" lastModificationDate="2017-11-06T00:00:00Z" phaseHighest="Discovery"><CompanyOriginator>Institute of Materia Medica Chinese Academy of Medical Sciences &amp; Peking Union Medical College</CompanyOriginator><CompaniesPrimary><Company>Institute of Materia Medica Chinese Academy of Medical Sciences &amp; Peking Union Medical College</Company></CompaniesPrimary><RegulatoryDesignations><RegulatoryDesignation>Fast Track</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication>Rheumatoid arthritis</Indication></IndicationsPrimary><Technologies><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><Summary>Institute of Materia Medica , in collaboration with Beijing Union Pharmaceutical Factory , is investigating an oral tablet formulation of pusaimode, a small molecule therapeutic, for the potential treatment of rheumatoid arthritis [ 1977138 ]. In November 2015, an IND applicationwas filed in China [ 1710021 ]; in November 2016, approval to conduct a clinical trial was obtained [ 1877233 ]. In October 2017, a phase Ia trial was planned in China [ 1977138 ].</Summary><ActionsSecondary><Action>Anti-inflammatory</Action><Action>Unspecified drug target</Action></ActionsSecondary><AddedDate>2015-11-23T00:00:00Z</AddedDate></Drug><Drug id="9990" name="cisplatin + epinephrine, Matrix" lastModificationDate="2016-11-26T00:00:00Z" phaseHighest="Discontinued"><CompanyOriginator>Matrix Pharmaceutical Inc</CompanyOriginator><RegulatoryDesignations><RegulatoryDesignation>Fast Track</RegulatoryDesignation><RegulatoryDesignation>Orphan Drug</RegulatoryDesignation></RegulatoryDesignations><Technologies><Technology>Drug combination</Technology><Technology>Drug implant</Technology><Technology>Injectable controlled release formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><Summary>IntraDose is an injectable, collagen gel-based drug delivery system which was under development by Matrix, and had been submitted for regulatory approval, for the potential delivery of anticancer drugs to solid tumors [ 303924 ], [ 304018 ]. In March 2002, Chiron acquired Matrix was seeking to outlicense IntraDose , although the submission was not withdrawn [ 445191 ], [ 445315 ], [ 455561 ]; however, by March 2003, Chiron had stopped development [ 481460 ].</Summary><CompaniesSecondary><Company>Chiron Corp</Company><Company>Matrix Pharmaceutical Inc</Company></CompaniesSecondary><IndicationsSecondary><Indication>Breast tumor</Indication><Indication>Esophagus tumor</Indication><Indication>Head and neck tumor</Indication><Indication>Liver tumor</Indication><Indication>Lung tumor</Indication><Indication>Melanoma</Indication><Indication>Neoplasm</Indication><Indication>Prostate tumor</Indication><Indication>Rectal tumor</Indication></IndicationsSecondary><ActionsSecondary><Action>Anticancer</Action><Action>Unspecified drug target</Action></ActionsSecondary><AddedDate>1996-02-16T00:00:00Z</AddedDate></Drug><Drug id="99650" name="naloxone (intranasal spray, opioid intoxication), Insys Therapeutics" lastModificationDate="2019-05-16T00:00:00Z" phaseHighest="Pre-registration"><CompanyOriginator>Insys Therapeutics Inc</CompanyOriginator><CompaniesPrimary><Company>Insys Therapeutics Inc</Company></CompaniesPrimary><RegulatoryDesignations><RegulatoryDesignation>Fast Track</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication>Opiate dependence</Indication></IndicationsPrimary><ActionsPrimary><Action>Opioid receptor antagonist</Action></ActionsPrimary><Technologies><Technology>Formulation aerosol</Technology><Technology>Nasal formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><Summary>Insys Therapeutics is developing an intranasal spray formulation of naloxone for the potential treatment of opioid intoxication [ 1707916 ]. By March 2019, the company had filed an NDA with the US FDA for naloxone nasal spray [ 2150572 ].</Summary><AddedDate>2015-10-30T00:00:00Z</AddedDate></Drug><Drug id="99643" name="olacaftor" lastModificationDate="2018-08-23T00:00:00Z" phaseHighest="Phase 2 Clinical"><CompanyOriginator>Vertex Pharmaceuticals Inc</CompanyOriginator><CompaniesPrimary><Company>Vertex Pharmaceuticals Inc</Company></CompaniesPrimary><RegulatoryDesignations><RegulatoryDesignation>Fast Track</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication>Cystic fibrosis</Indication></IndicationsPrimary><ActionsPrimary><Action>CFTR modulator</Action></ActionsPrimary><Technologies><Technology>Small molecule therapeutic</Technology><Technology>Systemic formulation unspecified</Technology></Technologies><Summary>Vertex Pharmaceuticals is developing olacaftor (VX-440), a next-generation corrector of the cystic fibrosis transmembrane regulator (CFTR) trafficking defect, for the potential treatment of cystic fibrosis (CF) [ 1707558 ], [ 1886000 ], [ 1903812 ]. In October 2016, the drug was listed as being in phase II development in triple combination with tezacaftor / ivacaftor [ 1867717 ], [ 2063580 ]; in July 2017, data were presented from the phase II study. At the time, discussions with regulatory</Summary><ActionsSecondary><Action>Respiratory system agent</Action></ActionsSecondary><AddedDate>2015-11-02T00:00:00Z</AddedDate></Drug><Drug id="99642" name="VX-152" lastModificationDate="2018-08-16T00:00:00Z" phaseHighest="Phase 2 Clinical"><CompanyOriginator>Vertex Pharmaceuticals Inc</CompanyOriginator><CompaniesPrimary><Company>Vertex Pharmaceuticals Inc</Company></CompaniesPrimary><RegulatoryDesignations><RegulatoryDesignation>Fast Track</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication>Cystic fibrosis</Indication></IndicationsPrimary><ActionsPrimary><Action>CFTR modulator</Action></ActionsPrimary><Technologies><Technology>Small molecule therapeutic</Technology><Technology>Systemic formulation unspecified</Technology></Technologies><Summary>Vertex Pharmaceuticals is developing VX-152, a lead from next-generation correctors of the cystic fibrosis transmembrane regulator (CFTR) trafficking defect, for the potential treatment of cystic fibrosis (CF) [ 1707558 ]. In October 2016, the drug was listed as being in phase II development in triple combination with tezacaftor / ivacaftor [ 1867717 ]; in July 2017, data were presented from the phase II study. At the time, discussions with regulatory agencies were planned, to initiate 'pivotal' studies</Summary><ActionsSecondary><Action>Respiratory system agent</Action></ActionsSecondary><AddedDate>2015-11-02T00:00:00Z</AddedDate></Drug><Drug id="99407" name="PTI-428" lastModificationDate="2019-06-11T00:00:00Z" phaseHighest="Phase 2 Clinical"><CompanyOriginator>Proteostasis Therapeutics Inc</CompanyOriginator><CompaniesPrimary><Company>Proteostasis Therapeutics Inc</Company></CompaniesPrimary><RegulatoryDesignations><RegulatoryDesignation>Breakthrough Therapy</RegulatoryDesignation><RegulatoryDesignation>Fast Track</RegulatoryDesignation><RegulatoryDesignation>Orphan Drug</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication>Cystic fibrosis</Indication></IndicationsPrimary><ActionsPrimary><Action>CFTR stimulator</Action></ActionsPrimary><Technologies><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><Summary>Proteostasis Therapeutics is developing PTI-428, a cystic fibrosis transmembrane conductance regulator (CFTR) amplifier, discovered through the company's disease-relevant translation (DRT) platform, for the potential oral treatment of cystic fibrosis [ 1701661 ]. In July 2016, a phase I/II trial was initiated [ 1747945 ]; in July 2017, positive preliminary data were reported [ 1949578 ]. In August 2018, a phase II trial of PTI-428 in patients receiving background therapy with tezacaftor + ivacaftor</Summary><AddedDate>2015-10-09T00:00:00Z</AddedDate></Drug><Drug id="99384" name="contezolid acefosamil" lastModificationDate="2019-02-04T00:00:00Z" phaseHighest="Phase 2 Clinical"><CompanyOriginator>MicuRx Pharmaceuticals Inc</CompanyOriginator><CompaniesPrimary><Company>MicuRx Pharmaceuticals Inc</Company></CompaniesPrimary><RegulatoryDesignations><RegulatoryDesignation>Fast Track</RegulatoryDesignation><RegulatoryDesignation>Qualified Infectious Disease Product</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication>Bacterial skin infection</Indication><Indication>Gram positive bacterium infection</Indication></IndicationsPrimary><Technologies><Technology>Antibiotic</Technology><Technology>Intravenous formulation</Technology><Technology>Prodrug</Technology><Technology>Small molecule therapeutic</Technology></Technologies><Summary>MicuRx Pharmaceuticals is developing contezolid acefosamil (MRX-IV), a water soluble, injectable prodrug of MRX-I , for the potential iv treatment of Gram positive bacterium infections, including MRSA and vancomycin-resistant enterococci (VRE). The company is also developing the drug, for the potential treatment of acute bacterial skin and skin structure infections (ABSSSI) [ 1701165 ], [ 1879637 ], [ 2074869 ]. In November 2018, a phase II trial was initiated in the US and a global phase III</Summary><ActionsSecondary><Action>Antibacterial</Action><Action>Unspecified drug target</Action></ActionsSecondary><AddedDate>2015-10-08T00:00:00Z</AddedDate></Drug><Drug id="99365" name="TK-216" lastModificationDate="2019-06-19T00:00:00Z" phaseHighest="Phase 1 Clinical"><CompanyOriginator>Tokalas Inc</CompanyOriginator><CompaniesPrimary><Company>Oncternal Therapeutics Inc</Company></CompaniesPrimary><RegulatoryDesignations><RegulatoryDesignation>Fast Track</RegulatoryDesignation><RegulatoryDesignation>Orphan Drug</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication>Acute myelogenous leukemia</Indication><Indication>Cancer</Indication><Indication>Ewing sarcoma</Indication></IndicationsPrimary><ActionsPrimary><Action>ETS transcription factor inhibitor</Action><Action>EWS Fli1 protein inhibitor</Action></ActionsPrimary><Technologies><Technology>Intravenous formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><Summary>Oncternal Therapeutics , following its merger with Tokalas , is developing TK-216, the lead from an ETS-family transcription factor inhibitor program, which targets the Ewing sarcoma breakpoint region 1 and Friend leukemia virus integration 1 (EWS-FLI1) fusion transcription factor, for the potential iv treatment of Ewing sarcoma (ES). The company is also investigating the drug for the potential treatment of other cancers, including glioblastoma, acute myeloid leukemia (AML), castration-resistant</Summary><CompaniesSecondary><Company>Tokalas Inc</Company></CompaniesSecondary><ActionsSecondary><Action>Anticancer</Action><Action>Synergist</Action></ActionsSecondary><AddedDate>2015-10-07T00:00:00Z</AddedDate></Drug><Drug id="99307" name="tideglusib (oral powder formulation, myotonic dystrophy/Autism), AMO Pharma" lastModificationDate="2019-05-13T00:00:00Z" phaseHighest="Phase 2 Clinical"><CompanyOriginator>AMO Pharma Ltd</CompanyOriginator><CompaniesPrimary><Company>AMO Pharma Ltd</Company></CompaniesPrimary><RegulatoryDesignations><RegulatoryDesignation>Fast Track</RegulatoryDesignation><RegulatoryDesignation>Orphan Drug</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication>Autism</Indication><Indication>Myotonic dystrophy</Indication></IndicationsPrimary><ActionsPrimary><Action>Glycogen synthase kinase-3 beta inhibitor</Action></ActionsPrimary><Technologies><Technology>Formulation powder</Technology><Technology>Oral formulation</Technology><Technology>Oral suspension formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><Summary>AMO Pharma is developing tideglusib (AMO-02), an inhibitor of glycogen synthase kinase 3 beta (GSK-3 beta), for the potential oral treatment of myotonic dystrophy and autism spectrum disorder (ASD) [ 1698921 ], [ 1789543 ], [ 2087808 ]. In August 2016, a phase II study in patients with congenital and juvenile-onset myotonic dystrophy, was initiated in the UK [ 1789567 ], [ 1789543 ]. In March 2018, data were reported and the company was planning to evaluate the efficacy of AMO-02 in larger</Summary><AddedDate>2015-10-01T00:00:00Z</AddedDate></Drug><Drug id="99256" name="benzhydrocodone hydrochloride (oral immediate release APAP-free formulation, pain), KemPharm" lastModificationDate="2018-08-14T00:00:00Z" phaseHighest="Phase 1 Clinical"><CompanyOriginator>KemPharm Inc</CompanyOriginator><CompaniesPrimary><Company>KemPharm Inc</Company></CompaniesPrimary><RegulatoryDesignations><RegulatoryDesignation>Fast Track</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication>Pain</Indication></IndicationsPrimary><Technologies><Technology>Oral formulation</Technology><Technology>Oral quick release formulation</Technology><Technology>Prodrug</Technology><Technology>Small molecule therapeutic</Technology></Technologies><Summary>KemPharm is developing KP-201/IR, using the company's ligand activated therapy (LAT) technology and Acura 's Aversion Technology, as an immediate release, acetaminophen (APAP)-free formulation of KP-201 , for the potential short-term management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate [ 1697573 ], [ 1796718 ], [ 1864378 ], [ 2019318 ]. In March 2017, data were reported from an intranasal human abuse liability study [ 1909233 ]. In</Summary><ActionsSecondary><Action>Analgesic</Action><Action>Unspecified drug target</Action></ActionsSecondary><AddedDate>2015-09-29T00:00:00Z</AddedDate></Drug><Drug id="9862" name="metreleptin" lastModificationDate="2019-02-11T00:00:00Z" phaseHighest="Launched"><CompanyOriginator>Rockefeller University</CompanyOriginator><CompaniesPrimary><Company>Aegerion Pharmaceuticals Inc</Company><Company>Shionogi &amp; Co Ltd</Company></CompaniesPrimary><RegulatoryDesignations><RegulatoryDesignation>Fast Track</RegulatoryDesignation><RegulatoryDesignation>Orphan Drug</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication>Leptin deficiency</Indication><Indication>Lipodystrophy</Indication></IndicationsPrimary><ActionsPrimary><Action>Leptin receptor agonist</Action></ActionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Daily dosing</Technology><Technology>Freeze drying</Technology><Technology>Protein recombinant</Technology><Technology>Subcutaneous formulation</Technology></Technologies><Summary>Now marketed by Novelion (formerly Aegerion), following development by former licensees Amylin and AstraZeneca under license from Rockefeller University , metreleptin (Myalept; Myalepta; AC-164594; r-metHuLeptin; native leptin) is a recombinant analog of the human hormone leptin produced in fat cells. The product is indicated in the US as replacement therapy to treat the complications of leptin deficiency, in addition to diet, in patients with congenital or acquired generalized lipodystrophy</Summary><CompaniesSecondary><Company>Amgen Inc</Company><Company>Amylin Pharmaceuticals Inc</Company><Company>AstraZeneca plc</Company><Company>Rockefeller University</Company></CompaniesSecondary><IndicationsSecondary><Indication>Amenorrhea</Indication><Indication>Insulin dependent diabetes</Indication><Indication>Non-insulin dependent diabetes</Indication><Indication>Obesity</Indication></IndicationsSecondary><ActionsSecondary><Action>Antihypertriglyceridemic agent</Action><Action>Appetite suppressant</Action><Action>Hypoglycemic agent</Action></ActionsSecondary><AddedDate>1996-02-16T00:00:00Z</AddedDate></Drug><Drug id="98615" name="trastuzumab deruxtecan" lastModificationDate="2019-06-04T00:00:00Z" phaseHighest="Phase 3 Clinical"><CompanyOriginator>Daiichi Sankyo Co Ltd</CompanyOriginator><CompaniesPrimary><Company>AstraZeneca plc</Company><Company>Daiichi Sankyo Co Ltd</Company></CompaniesPrimary><RegulatoryDesignations><RegulatoryDesignation>Breakthrough Therapy</RegulatoryDesignation><RegulatoryDesignation>Fast Track</RegulatoryDesignation><RegulatoryDesignation>Sakigake</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication>Advanced solid tumor</Indication><Indication>Biliary cancer</Indication><Indication>Carcinosarcoma</Indication><Indication>Colorectal tumor</Indication><Indication>Metastatic breast cancer</Indication><Indication>Metastatic non small cell lung cancer</Indication><Indication>Stomach tumor</Indication><Indication>Transitional cell carcinoma</Indication><Indication>Uterus tumor</Indication></IndicationsPrimary><ActionsPrimary><Action>Erbb2 tyrosine kinase receptor inhibitor</Action><Action>Topoisomerase I inhibitor</Action></ActionsPrimary><Technologies><Technology>Antibody drug conjugate</Technology><Technology>Biological therapeutic</Technology><Technology>Freeze drying</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Monoclonal antibody conjugated</Technology><Technology>Monoclonal antibody humanized</Technology><Technology>Protein recombinant</Technology></Technologies><Summary>Daiichi Sankyo and licensee AstraZeneca are developing trastuzumab deruxtecan (DS-8201, DS-8201a), a HER2-targeting antibody-drug conjugate composed of the humanized anti-HER2 antibody trastuzumab attached via an enzymatically cleavable peptide-linker to a novel topoisomerase I inhibitor, exatecan (DX-8951), for the potential iv treatment of advanced solid tumors, including breast cancer, gastric cancer, colorectal cancer, metastatic NSCLC, transitional cell carcinoma and HER2-positive biliary</Summary><ActionsSecondary><Action>Anticancer monoclonal antibody</Action><Action>Anticancer protein kinase inhibitor</Action><Action>Apoptosis stimulator</Action></ActionsSecondary><AddedDate>2015-10-22T00:00:00Z</AddedDate></Drug><Drug id="98429" name="SER-287" lastModificationDate="2019-05-13T00:00:00Z" phaseHighest="Phase 2 Clinical"><CompanyOriginator>Seres Therapeutics Inc</CompanyOriginator><CompaniesPrimary><Company>Nestle Health Science</Company><Company>Seres Therapeutics Inc</Company></CompaniesPrimary><RegulatoryDesignations><RegulatoryDesignation>Fast Track</RegulatoryDesignation><RegulatoryDesignation>Orphan Drug</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication>Crohns disease</Indication><Indication>Inflammatory bowel disease</Indication><Indication>Ulcerative colitis</Indication></IndicationsPrimary><Technologies><Technology>Bacterium novel</Technology><Technology>Biological therapeutic</Technology><Technology>Capsule formulation</Technology><Technology>Cell therapy</Technology><Technology>Oral formulation</Technology></Technologies><Summary>Seres Therapeutics is developing the ecobiotic SER-287, comprising an encapsulated purified suspension of eubacterial spores developed using its Microbiome Therapeutics platform, for the potential oral treatment of ulcerative colitis (UC) [ 1680455 ]. Licensee Nestle Health Science is also investigating the program outside of the US and Canada [ 1726371 ]. In December 2018, a phase II trial was initiated in patients with active mild-to-moderate ulcerative colitis [ 2101067 ]. In October 2017, the</Summary><ActionsSecondary><Action>Anti-inflammatory</Action><Action>Antibacterial</Action><Action>Microbiome modulator</Action></ActionsSecondary><AddedDate>2015-11-11T00:00:00Z</AddedDate></Drug><Drug id="98351" name="umibecestat" lastModificationDate="2019-05-13T00:00:00Z" phaseHighest="Phase 3 Clinical"><CompanyOriginator>Novartis AG</CompanyOriginator><CompaniesPrimary><Company>Amgen Inc</Company><Company>Novartis AG</Company></CompaniesPrimary><RegulatoryDesignations><RegulatoryDesignation>Fast Track</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication>Alzheimers disease</Indication></IndicationsPrimary><ActionsPrimary><Action>Beta secretase 1 inhibitor</Action></ActionsPrimary><Technologies><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><Summary>Novartis , in collaboration with Amgen , is developing umibecestat (AMG-520; CNP-520), a small molecule beta secretase (BACE)-1 inhibitor, for the potential oral treatment of Alzheimer's disease (AD) [ 1706826 ], [ 1741336 ]. In November 2015, a phase II/III trial in patients at risk for onset of clinical symptoms of AD was initiated as part of the Alzheimer's Prevention Initiative (API) program [ 1732337 ]. In June 2017, a second pivotal phase II/III trial in individuals at risk of clinical</Summary><ActionsSecondary><Action>Neuroprotectant</Action></ActionsSecondary><AddedDate>2015-08-01T00:00:00Z</AddedDate></Drug><Drug id="98214" name="imipenem + relebactam + cilastatin" lastModificationDate="2019-06-21T00:00:00Z" phaseHighest="Pre-registration"><CompanyOriginator>Merck Sharp &amp; Dohme Corp</CompanyOriginator><CompaniesPrimary><Company>Merck Sharp &amp; Dohme Corp</Company></CompaniesPrimary><RegulatoryDesignations><RegulatoryDesignation>Fast Track</RegulatoryDesignation><RegulatoryDesignation>Priority Review</RegulatoryDesignation><RegulatoryDesignation>Qualified Infectious Disease Product</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication>Bacterial infection</Indication><Indication>Bacterial pneumonia</Indication><Indication>Complicated urinary tract infection</Indication><Indication>Gram negative bacterium infection</Indication></IndicationsPrimary><ActionsPrimary><Action>Beta lactamase inhibitor</Action><Action>Dehydropeptidase-1 inhibitor</Action></ActionsPrimary><Technologies><Technology>Antibiotic</Technology><Technology>Drug combination</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><Summary>Merck Sharp &amp;amp; Dohme (a subsidiary of Merck &amp;amp; Co ) is developing MK-7655A (IMI/REL), a fixed-dose combination of imipenem, a thienamycin derivative with potent broad-spectrum antibacterial activity, relebactam , a beta-lactamase class A and C inhibitor, and cilastatin, a renal enzyme inhibitor included to provide pharmacological benefit, for the potential iv treatment of serious or complicated bacterial infections, including hospital-acquired bacterial pneumonia (HABP), ventilator-associated</Summary><ActionsSecondary><Action>Antibacterial</Action><Action>Bacterial cell wall synthesis inhibitor</Action><Action>Beta lactam antibiotic</Action><Action>Carbapenem</Action></ActionsSecondary><AddedDate>2015-08-01T00:00:00Z</AddedDate></Drug><Drug id="9820" name="neridronic acid" lastModificationDate="2019-01-08T00:00:00Z" phaseHighest="Launched"><CompanyOriginator>Istituto Gentili SpA</CompanyOriginator><CompaniesPrimary><Company>Abiogen Pharma SpA</Company><Company>Grunenthal GmbH</Company><Company>Lee's Pharmaceutical Holdings Limited</Company></CompaniesPrimary><RegulatoryDesignations><RegulatoryDesignation>Breakthrough Therapy</RegulatoryDesignation><RegulatoryDesignation>Fast Track</RegulatoryDesignation><RegulatoryDesignation>Orphan Drug</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication>Complex regional pain syndrome</Indication><Indication>Osteogenesis imperfecta</Indication><Indication>Pagets bone disease</Indication><Indication>Type I complex regional pain syndrome</Indication></IndicationsPrimary><Technologies><Technology>Intramuscular formulation</Technology><Technology>Intravenous formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><Summary>Grunenthal , under license from Shire (originally licensed from Istituto Gentili ), and Abiogen , have developed and launched im neridronic acid (Attila; Abioklad formerly Nerixia), an aminobisphosphonate capable of reducing fractures, for the treatment of osteogenesis and Paget's bone disease [ 887982 ] [ 1886072 ]. The drug was launched in Italy for the treatment of osteogenesis imperfecta by April 2002. The product was first registered in Italy in 2002 as Nerixia [ 454647 ], [ 553220</Summary><CompaniesSecondary><Company>Istituto Gentili SpA</Company><Company>Shire Pharmaceutical Development Ltd</Company></CompaniesSecondary><IndicationsSecondary><Indication>Ostealgia</Indication><Indication>Osteoporosis</Indication></IndicationsSecondary><ActionsSecondary><Action>Bone modulator</Action><Action>Bone resorption inhibitor</Action><Action>Calcium metabolism modulator</Action><Action>Osteoclast inhibitor</Action></ActionsSecondary><AddedDate>1996-02-16T00:00:00Z</AddedDate></Drug><Drug id="9798" name="lucinactant (liquid instillate), Windtree Therapeutics/ Esteve/ Lee's Pharmaceutical" lastModificationDate="2019-05-03T00:00:00Z" phaseHighest="Launched"><CompanyOriginator>Scripps Research Institute</CompanyOriginator><CompaniesPrimary><Company>Lee's Pharmaceutical Holdings Limited</Company><Company>Windtree Therapeutics Inc</Company></CompaniesPrimary><RegulatoryDesignations><RegulatoryDesignation>Fast Track</RegulatoryDesignation><RegulatoryDesignation>Orphan Drug</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication>Acute lung injury</Indication><Indication>Neonatal respiratory distress syndrome</Indication></IndicationsPrimary><ActionsPrimary><Action>Bone morphogenetic protein-10 ligand inhibitor</Action><Action>Bone morphogenetic protein-15 ligand inhibitor</Action><Action>Lung surfactant associated protein B stimulator</Action></ActionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Freeze drying</Technology><Technology>Lipid</Technology><Technology>Liquid-based formulation technology</Technology><Technology>Local formulation unspecified</Technology><Technology>Protein recombinant</Technology><Technology>Suspension</Technology><Technology>Systemic formulation unspecified</Technology></Technologies><Summary>Windtree Therapeutics (formerly Discovery Laboratories ; Acute Therapeutics Inc ), in collaboration with Laboratorios Dr Esteve , has developed and launched BMP10- and BMP15-inhibiting lucinactant (KL4 surfactant; Surfaxin), in liquid instillate form (and as a lyophilized dry powder formulation (Surfaxin LS) which is reconstituted as a liquid prior to administration [ 991601 ]) containing sinapultide (structure shown), a human surfactant protein B mimetic identified at the Scripps Research Institute</Summary><CompaniesSecondary><Company>Acute Therapeutics Inc</Company><Company>Johnson &amp; Johnson</Company><Company>Laboratorios Dr Esteve SA</Company><Company>Scripps Research Institute</Company></CompaniesSecondary><IndicationsSecondary><Indication>Cystic fibrosis</Indication><Indication>Lung malformation</Indication><Indication>Meconium aspiration syndrome</Indication><Indication>Respiratory disease</Indication><Indication>Respiratory distress syndrome</Indication><Indication>Respiratory insufficiency</Indication></IndicationsSecondary><ActionsSecondary><Action>Anti-inflammatory</Action><Action>Respiratory system agent</Action><Action>Surfactant</Action></ActionsSecondary><AddedDate>1996-02-16T00:00:00Z</AddedDate></Drug><Drug id="97846" name="cycloserine + lurasidone (bipolar depression, suicidality), NeuroRx" lastModificationDate="2019-06-11T00:00:00Z" phaseHighest="Phase 3 Clinical"><CompanyOriginator>NeuroRx Inc</CompanyOriginator><CompaniesPrimary><Company>NeuroRx Inc</Company></CompaniesPrimary><RegulatoryDesignations><RegulatoryDesignation>Breakthrough Therapy</RegulatoryDesignation><RegulatoryDesignation>Fast Track</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication>Bipolar disorder</Indication><Indication>Suicidal ideation</Indication></IndicationsPrimary><ActionsPrimary><Action>5-HT 1a receptor partial agonist</Action><Action>5-HT 2a receptor antagonist</Action><Action>5-HT 7 receptor antagonist</Action><Action>Alpha 2C adrenoceptor antagonist</Action><Action>Dopamine D2 receptor antagonist</Action><Action>NMDA receptor modulator</Action></ActionsPrimary><Technologies><Technology>Capsule formulation</Technology><Technology>Drug combination</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Sustained release formulation</Technology></Technologies><Summary>NeuroRx is developing NRX-101 (Cyclurad), a repurposed proprietary formulation of D-cycloserine (cycloserine) and lurasidone (5-HT2a receptor antagonist), which targets NMDA receptor, as part of a sequential regimen followed by a single iv infusion of the approved anesthetic ketamine HCl (NRX-100), for the potential sustained oral treatment of bipolar depression and sucidality [ 1672948 ], [ 1721957 ], [ 1864177 ], [ 1994591 ], [ 2104186 ]. In June 2018, a phase IIb/III trial was initiated</Summary><ActionsSecondary><Action>Antidepressant</Action><Action>Antipsychotic</Action><Action>Nootropic agent</Action></ActionsSecondary><AddedDate>2015-06-26T00:00:00Z</AddedDate></Drug><Drug id="97792" name="tropifexor" lastModificationDate="2019-04-25T00:00:00Z" phaseHighest="Phase 2 Clinical"><CompanyOriginator>Novartis AG</CompanyOriginator><CompaniesPrimary><Company>Novartis AG</Company></CompaniesPrimary><RegulatoryDesignations><RegulatoryDesignation>Fast Track</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication>Diarrhea</Indication><Indication>Liver fibrosis</Indication><Indication>Non-alcoholic steatohepatitis</Indication><Indication>Primary biliary cholangitis</Indication></IndicationsPrimary><ActionsPrimary><Action>Farnesoid X receptor agonist</Action></ActionsPrimary><Technologies><Technology>Capsule formulation</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><Summary>Novartis is developing tropifexor (LJN-452), a non-bile acid farnesoid X receptor (FXR) agonist, and its analog LJP-305, for the potential oral treatment of nonalcoholic steatohepatitis (NASH), primary biliary cirrhosis (PBC), liver fibrosis and bile acid diarrhea [ 1671972 ], [ 1685581 ], [ 1748226 ], [ 2040453 ]. In September 2015, a phase II trial was initiated in the US in patients with PBC [ 1685581 ]. In January 2016, the drug was listed as being in phase II development for NASH [ 1730419 ]; in</Summary><ActionsSecondary><Action>Anti-inflammatory</Action><Action>Fibrosuppressant</Action></ActionsSecondary><AddedDate>2015-06-22T00:00:00Z</AddedDate></Drug><Drug id="97243" name="tafenoquine (oral tablet, malaria), 60° Pharmaceuticals/United States Army/Biocelect" lastModificationDate="2019-04-17T00:00:00Z" phaseHighest="Launched"><CompanyOriginator>60° Pharmaceuticals LLC</CompanyOriginator><CompaniesPrimary><Company>60° Pharmaceuticals LLC</Company><Company>Biocelect</Company><Company>United States Army</Company></CompaniesPrimary><RegulatoryDesignations><RegulatoryDesignation>Fast Track</RegulatoryDesignation><RegulatoryDesignation>Priority Review</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication>Plasmodium infection</Indication></IndicationsPrimary><Technologies><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><Summary>60° Pharmaceuticals , United States Army and Australian-license Biocelect have developed and launched Arakoda (KODATEF; 60-P003), an oral tablet formulation of tafenoquine , a DNA synthesis inhibitor, for the prevention of malaria [ 1663475 ], [ 1663494 ], [ 2057554 ], [ 2108100 ], [ 2131788 ]. In March 2019, the drug was launched in Australia by 60° Pharmaceuticals and Biocelect [ 2131788 ]. In August 2018, the US FDA approved Arakoda for the prevention of malaria in patients aged 18 years and older</Summary><ActionsSecondary><Action>Antiparasitic</Action><Action>DNA synthesis inhibitor</Action><Action>Fungicide</Action></ActionsSecondary><AddedDate>2015-05-13T00:00:00Z</AddedDate></Drug></SearchResults><Filters total="15"><Filter label="Drug Sales 2010 (USD M)" name="drugSalesYearActual" total="5"><FilterOption count="236" label="&lt; 100"/><FilterOption count="17" label="≥ 100 and  250"/><FilterOption count="16" label="≥ 250 and  500"/><FilterOption count="16" label="≥ 500 and  1000"/><FilterOption count="19" label="≥ 1000"/></Filter><Filter label="Secondary Actions" name="actionsSecondary" total="100"><FilterOption id="1545" count="253" label="Anticancer"/><FilterOption id="2953" count="177" label="Anti-inflammatory"/><FilterOption id="1594" count="92" label="Antibacterial"/><FilterOption id="991" count="83" label="Antiviral"/><FilterOption id="1615" count="73" label="Neuroprotectant"/><FilterOption id="59620" count="66" label="Unspecified drug target"/><FilterOption id="62255" count="65" label="Anticancer protein kinase inhibitor"/><FilterOption id="7293" count="55" label="Synergist"/><FilterOption id="2946" count="51" label="Analgesic"/><FilterOption id="1589" count="51" label="Apoptosis stimulator"/><FilterOption id="55685" count="48" label="Anticancer monoclonal antibody"/><FilterOption id="61" count="42" label="Angiogenesis inhibitor"/><FilterOption id="1596" count="41" label="Immunomodulator"/><FilterOption id="12379" count="40" label="Therapeutic vaccine"/><FilterOption id="393" count="34" label="Immunostimulant"/><FilterOption id="12378" count="33" label="Prophylactic vaccine"/><FilterOption id="284" count="30" label="Nootropic agent"/><FilterOption id="4781" count="27" label="Adeno-associated virus based gene therapy"/><FilterOption id="2947" count="24" label="Antiparkinsonian"/><FilterOption id="2657" count="23" label="Antihypertensive"/><FilterOption id="1748" count="23" label="Fungicide"/><FilterOption id="7761" count="23" label="T-lymphocyte stimulator"/><FilterOption id="399" count="22" label="Hypoglycemic agent"/><FilterOption id="396" count="22" label="Immunosuppressant"/><FilterOption id="15128" count="21" label="Ophthalmological agent"/><FilterOption id="70" count="19" label="Anticonvulsant agent"/><FilterOption id="2659" count="18" label="Cardioprotectant"/><FilterOption id="12372" count="18" label="Protein subunit vaccine"/><FilterOption id="2941" count="17" label="Antidepressant"/><FilterOption id="1538" count="16" label="Bacterial protein synthesis inhibitor"/><FilterOption id="767" count="16" label="Cell cycle inhibitor"/><FilterOption id="664" count="16" label="Fibrosuppressant"/><FilterOption id="140" count="15" label="DNA synthesis inhibitor"/><FilterOption id="15184" count="15" label="Systemic antipsoriatic product"/><FilterOption id="50" count="14" label="Anticancer alkylating agent"/><FilterOption id="2943" count="13" label="Antipsychotic"/><FilterOption id="104" count="13" label="Bacterial cell wall synthesis inhibitor"/><FilterOption id="463" count="13" label="Ribosome binding agent"/><FilterOption id="15187" count="13" label="Systemic dermatological antibacterial product"/><FilterOption id="7292" count="13" label="Vulnerary agent"/><FilterOption id="659" count="12" label="Coagulation inhibitor"/><FilterOption id="1332" count="12" label="Gastrointestinal system agent"/><FilterOption id="1470" count="12" label="Respiratory system agent"/><FilterOption id="388" count="12" label="Vasodilator"/><FilterOption id="7294" count="11" label="Antisense oligonucleotide inhibitor"/><FilterOption id="4790" count="11" label="Genetically engineered autologous cell therapy"/><FilterOption id="7220" count="11" label="Neoplasm diagnostic agent"/><FilterOption id="2638" count="10" label="Antiparasitic"/><FilterOption id="1590" count="10" label="Apoptosis inhibitor"/><FilterOption id="539" count="10" label="Immunotoxin"/><FilterOption id="1408" count="10" label="Muscle system agent"/><FilterOption id="2660" count="10" label="Vasoprotectant"/><FilterOption id="2939" count="9" label="CNS modulator"/><FilterOption id="15148" count="9" label="Ocular antineovascularisation agent"/><FilterOption id="1465" count="9" label="Radioprotectant"/><FilterOption id="2954" count="9" label="Steroidal anti-inflammatory"/><FilterOption id="4780" count="8" label="Adenovirus based gene therapy"/><FilterOption id="62" count="8" label="Angiogenesis stimulator"/><FilterOption id="55684" count="8" label="Anticancer antibody"/><FilterOption id="750" count="8" label="DNA intercalator"/><FilterOption id="7213" count="8" label="Gastrointestinal diagnostic agent"/><FilterOption id="1389" count="8" label="Lipid metabolism modulator"/><FilterOption id="74" count="7" label="Antioxidant agent"/><FilterOption id="2942" count="7" label="Anxiolytic"/><FilterOption id="3984" count="7" label="Bacterial nucleic acid synthesis inhibitor"/><FilterOption id="1535" count="7" label="Beta lactam antibiotic"/><FilterOption id="1546" count="7" label="Blood system agent"/><FilterOption id="1276" count="7" label="Chemoprotectant"/><FilterOption id="7212" count="7" label="Endocrine diagnostic agent"/><FilterOption id="610" count="7" label="Hematopoietic stimulator"/><FilterOption id="2575" count="7" label="Microtubule inhibitor"/><FilterOption id="799" count="7" label="Photosensitizer"/><FilterOption id="4788" count="7" label="Plasmid based gene therapy"/><FilterOption id="339" count="7" label="Protein synthesis inhibitor"/><FilterOption id="12370" count="7" label="Recombinant viral vector vaccine"/><FilterOption id="1539" count="7" label="Tetracycline"/><FilterOption id="1541" count="6" label="Aminoglycoside antibiotic"/><FilterOption id="15319" count="6" label="Hepatitis C virus replication inhibitor"/><FilterOption id="695" count="6" label="Metastasis inhibitor"/><FilterOption id="959" count="6" label="Protectant"/><FilterOption id="1532" count="6" label="Viral replication inhibitor"/><FilterOption id="3" count="5" label="5-HT uptake inhibitor"/><FilterOption id="1569" count="5" label="Anticancer antimetabolite"/><FilterOption id="1586" count="5" label="Anticancer chemosensitizer"/><FilterOption id="4007" count="5" label="Antidiarrhoeal"/><FilterOption id="7243" count="5" label="Antidote"/><FilterOption id="7018" count="5" label="Antihypertriglyceridemic agent"/><FilterOption id="955" count="5" label="Antimicrobial permeability enhancer"/><FilterOption id="166" count="5" label="Fibrinolysis stimulator"/><FilterOption id="793" count="5" label="Gastroprokinetic"/><FilterOption id="3980" count="5" label="HIV fusion inhibitor"/><FilterOption id="12364" count="5" label="Live attenuated viral vaccine"/><FilterOption id="173474" count="5" label="Microbiome modulator"/><FilterOption id="1552" count="5" label="Radioimmunotherapeutic"/><FilterOption id="4782" count="5" label="Retrovirus based gene therapy"/><FilterOption id="26035" count="5" label="siRNA agent"/><FilterOption id="2969" count="5" label="Vascular damaging agent"/><FilterOption id="524" count="4" label="Adjuvant"/><FilterOption id="449" count="4" label="Antiarrhythmic agent"/><FilterOption id="62253" count="4" label="Anticancer hormone"/></Filter><Filter label="Drug Deal Types" name="drugDealTypes" total="20"><FilterOption id="4" count="501" label="Drug - Development/Commercialization License"/><FilterOption id="13" count="358" label="Drug - Funding"/><FilterOption id="6" count="277" label="Drug - Manufacturing/Supply"/><FilterOption id="7" count="243" label="Drug - Development Services"/><FilterOption id="3" count="218" label="Drug - Early Research/Development"/><FilterOption id="5" count="179" label="Drug - Commercialization License"/><FilterOption id="10" count="150" label="Technology - Other Proprietary"/><FilterOption id="11" count="125" label="Patent - Exclusive Rights"/><FilterOption id="2" count="113" label="Drug - Screening/Evaluation"/><FilterOption id="14" count="62" label="Drug - Asset Divestment"/><FilterOption id="15" count="59" label="Drug - CRADA"/><FilterOption id="8" count="57" label="Technology - Delivery/Formulation"/><FilterOption id="20" count="37" label="Company - M&amp;A (in whole or part)"/><FilterOption id="12" count="25" label="Patent - Non-Exclusive Rights"/><FilterOption id="1" count="15" label="Drug - Discovery/Design"/><FilterOption id="19" count="10" label="Company - Joint Venture"/><FilterOption id="16" count="8" label="Technology - Asset Divestment"/><FilterOption id="21" count="4" label="Patent - Litigation Settlement"/><FilterOption id="9" count="4" label="Technology - Target Validation"/><FilterOption id="17" count="3" label="Patent - Asset Divestment"/></Filter><Filter label="Drug Forecast 2015 (USD M)" name="drugSalesYearEstimate" total="5"><FilterOption count="125" label="&lt; 100"/><FilterOption count="40" label="≥ 100 and  250"/><FilterOption count="29" label="≥ 250 and  500"/><FilterOption count="20" label="≥ 500 and  1000"/><FilterOption count="30" label="≥ 1000"/></Filter><Filter label="Drug Deals Count" name="drugDealsCount" total="8"><FilterOption count="145" label="= 0"/><FilterOption count="178" label="&gt; 1 and ≤ 1"/><FilterOption count="159" label="&gt; 2 and ≤ 2"/><FilterOption count="141" label="&gt; 3 and ≤ 3"/><FilterOption count="95" label="&gt; 4 and ≤ 4"/><FilterOption count="55" label="&gt; 5 and ≤ 5"/><FilterOption count="167" label="&gt; 6 and ≤ 10"/><FilterOption count="75" label="&gt; 11"/></Filter><Filter label="Technologies" name="technologies" total="100"><FilterOption id="762" count="579" label="Small molecule therapeutic"/><FilterOption id="761" count="431" label="Biological therapeutic"/><FilterOption id="585" count="360" label="Oral formulation"/><FilterOption id="648" count="352" label="Intravenous formulation"/><FilterOption id="740" count="236" label="Infusion"/><FilterOption id="595" count="145" label="Tablet formulation"/><FilterOption id="586" count="113" label="Capsule formulation"/><FilterOption id="647" count="102" label="Subcutaneous formulation"/><FilterOption id="66" count="80" label="Antibiotic"/><FilterOption id="85" count="78" label="Protein recombinant"/><FilterOption id="80" count="73" label="Peptide"/><FilterOption id="766" count="60" label="Parenteral formulation unspecified"/><FilterOption id="573" count="57" label="Immunoglobulin-G"/><FilterOption id="746" count="53" label="Solution"/><FilterOption id="62" count="52" label="Virus recombinant"/><FilterOption id="651" count="48" label="Intramuscular formulation"/><FilterOption id="1652" count="48" label="Prodrug"/><FilterOption id="168" count="45" label="Monoclonal antibody human"/><FilterOption id="175" count="42" label="Drug combination"/><FilterOption id="1263" count="39" label="Immuno-oncology"/><FilterOption id="589" count="38" label="Sustained release formulation"/><FilterOption id="898" count="37" label="Formulation powder"/><FilterOption id="751" count="36" label="Film coating"/><FilterOption id="169" count="34" label="Monoclonal antibody humanized"/><FilterOption id="750" count="32" label="Freeze drying"/><FilterOption id="84" count="31" label="Protein fusion"/><FilterOption id="901" count="29" label="Recombinant enzyme"/><FilterOption id="616" count="25" label="Inhalant formulation"/><FilterOption id="1647" count="25" label="Natural product"/><FilterOption id="620" count="25" label="Ophthalmic formulation"/><FilterOption id="596" count="24" label="Injectable formulation"/><FilterOption id="611" count="22" label="Dermatological formulation"/><FilterOption id="570" count="21" label="Cell therapy"/><FilterOption id="764" count="21" label="Local formulation unspecified"/><FilterOption id="103" count="21" label="Oligonucleotide"/><FilterOption id="180" count="20" label="Antibody fragment"/><FilterOption id="599" count="19" label="Nanoparticle formulation injectable"/><FilterOption id="593" count="19" label="Oral liquid formulation"/><FilterOption id="603" count="19" label="Systemic formulation unspecified"/><FilterOption id="745" count="18" label="Suspension"/><FilterOption id="805" count="17" label="Daily dosing"/><FilterOption id="851" count="17" label="Intradermal formulation"/><FilterOption id="347" count="15" label="Intratumoral formulation"/><FilterOption id="594" count="15" label="Oral suspension formulation"/><FilterOption id="660" count="15" label="Oral sustained release formulation"/><FilterOption id="171" count="14" label="Monoclonal antibody conjugated"/><FilterOption id="569" count="14" label="Oligonucleotide antisense"/><FilterOption id="348" count="14" label="PEGylated formulation"/><FilterOption id="349" count="13" label="Lipid"/><FilterOption id="90" count="13" label="Steroid"/><FilterOption id="166" count="12" label="Chimeric monoclonal antibody"/><FilterOption id="207" count="12" label="Protein conjugated"/><FilterOption id="558" count="12" label="Transdermal formulation"/><FilterOption id="67" count="11" label="Antigen"/><FilterOption id="724" count="11" label="Radiolabeling"/><FilterOption id="135" count="11" label="T-lymphocyte"/><FilterOption id="617" count="10" label="Aerosol formulation inhalant"/><FilterOption id="731" count="10" label="Imaging"/><FilterOption id="93" count="10" label="Toxin"/><FilterOption id="582" count="9" label="Antibody polyclonal"/><FilterOption id="74" count="9" label="Glycoprotein"/><FilterOption id="743" count="9" label="Granule"/><FilterOption id="884" count="9" label="Haematopoietic stem cell therapy"/><FilterOption id="654" count="9" label="Intrathecal formulation"/><FilterOption id="159" count="9" label="Oligosaccharide"/><FilterOption id="641" count="8" label="Controlled release formulation"/><FilterOption id="775" count="8" label="Dermatological gel formulation"/><FilterOption id="852" count="8" label="Intravesical formulation"/><FilterOption id="667" count="8" label="Peptidomimetic"/><FilterOption id="856" count="7" label="Autologous stem cell therapy"/><FilterOption id="680" count="7" label="Buccal formulation systemic"/><FilterOption id="590" count="7" label="Enteric coated formulation"/><FilterOption id="1646" count="7" label="Injectable controlled release formulation"/><FilterOption id="142" count="7" label="Liposome formulation"/><FilterOption id="559" count="7" label="Oral controlled release formulation"/><FilterOption id="661" count="7" label="Oral quick release formulation"/><FilterOption id="1653" count="7" label="Tumor antigen"/><FilterOption id="857" count="6" label="Allogenic stem cell therapy"/><FilterOption id="56" count="6" label="Bacteria recombinant"/><FilterOption id="72" count="6" label="Enzyme"/><FilterOption id="656" count="6" label="Ophthalmic drug implant"/><FilterOption id="659" count="6" label="Ophthalmic liquid formulation"/><FilterOption id="618" count="6" label="Powder formulation inhalant"/><FilterOption id="630" count="6" label="Stereochemistry"/><FilterOption id="1655" count="6" label="Tumor antigen therapeutic"/><FilterOption id="127" count="5" label="Cell culture"/><FilterOption id="1656" count="5" label="CNS formulation"/><FilterOption id="864" count="5" label="Mesenchymal stem cell therapy"/><FilterOption id="753" count="5" label="Microparticle formulation"/><FilterOption id="1668" count="5" label="Nanoparticle formulation"/><FilterOption id="777" count="5" label="Nasal formulation"/><FilterOption id="216" count="4" label="Antibody conjugated"/><FilterOption id="1651" count="4" label="Blood constituents"/><FilterOption id="609" count="4" label="Buccal formulation local"/><FilterOption id="128" count="4" label="Cell culture technique"/><FilterOption id="1672" count="4" label="Directed prodrug therapy"/><FilterOption id="723" count="4" label="Drug coating"/><FilterOption id="612" count="4" label="Emulsion dermatological"/><FilterOption id="897" count="4" label="Formulation aerosol"/><FilterOption id="853" count="4" label="Intracoronary formulation"/></Filter><Filter label="Drug Added by Day" name="drugAddedDateByDay" total="100"><FilterOption count="103" label="1996-02-16"/><FilterOption count="5" label="2015-05-13"/><FilterOption count="4" label="2014-04-09"/><FilterOption count="4" label="2014-09-18"/><FilterOption count="4" label="2015-05-14"/><FilterOption count="3" label="1996-04-25"/><FilterOption count="3" label="2003-10-30"/><FilterOption count="3" label="2015-08-01"/><FilterOption count="3" label="2015-11-24"/><FilterOption count="3" label="2016-08-31"/><FilterOption count="2" label="1996-04-01"/><FilterOption count="2" label="1996-05-24"/><FilterOption count="2" label="1996-08-27"/><FilterOption count="2" label="1998-01-21"/><FilterOption count="2" label="1998-02-02"/><FilterOption count="2" label="1998-05-06"/><FilterOption count="2" label="1998-11-03"/><FilterOption count="2" label="1998-11-19"/><FilterOption count="2" label="1999-06-07"/><FilterOption count="2" label="2000-03-01"/><FilterOption count="2" label="2000-07-25"/><FilterOption count="2" label="2001-09-03"/><FilterOption count="2" label="2001-10-22"/><FilterOption count="2" label="2001-12-11"/><FilterOption count="2" label="2002-09-30"/><FilterOption count="2" label="2002-10-29"/><FilterOption count="2" label="2003-03-19"/><FilterOption count="2" label="2003-05-12"/><FilterOption count="2" label="2003-07-03"/><FilterOption count="2" label="2004-03-12"/><FilterOption count="2" label="2005-03-09"/><FilterOption count="2" label="2005-06-22"/><FilterOption count="2" label="2005-12-15"/><FilterOption count="2" label="2006-07-03"/><FilterOption count="2" label="2006-08-09"/><FilterOption count="2" label="2007-01-19"/><FilterOption count="2" label="2007-09-21"/><FilterOption count="2" label="2007-10-16"/><FilterOption count="2" label="2007-11-23"/><FilterOption count="2" label="2008-05-08"/><FilterOption count="2" label="2008-06-25"/><FilterOption count="2" label="2008-09-25"/><FilterOption count="2" label="2009-01-14"/><FilterOption count="2" label="2009-02-19"/><FilterOption count="2" label="2010-05-18"/><FilterOption count="2" label="2011-03-11"/><FilterOption count="2" label="2011-03-30"/><FilterOption count="2" label="2011-05-04"/><FilterOption count="2" label="2011-06-07"/><FilterOption count="2" label="2011-12-21"/><FilterOption count="2" label="2013-10-18"/><FilterOption count="2" label="2014-09-09"/><FilterOption count="2" label="2014-11-25"/><FilterOption count="2" label="2015-10-22"/><FilterOption count="2" label="2016-06-27"/><FilterOption count="2" label="2016-10-27"/><FilterOption count="1" label="1996-03-08"/><FilterOption count="1" label="1996-03-12"/><FilterOption count="1" label="1996-03-28"/><FilterOption count="1" label="1996-05-14"/><FilterOption count="1" label="1996-06-12"/><FilterOption count="1" label="1996-06-27"/><FilterOption count="1" label="1996-06-30"/><FilterOption count="1" label="1996-07-01"/><FilterOption count="1" label="1996-07-25"/><FilterOption count="1" label="1996-08-15"/><FilterOption count="1" label="1996-08-19"/><FilterOption count="1" label="1996-09-09"/><FilterOption count="1" label="1996-09-13"/><FilterOption count="1" label="1996-09-20"/><FilterOption count="1" label="1996-10-08"/><FilterOption count="1" label="1996-10-10"/><FilterOption count="1" label="1996-10-15"/><FilterOption count="1" label="1996-10-21"/><FilterOption count="1" label="1996-11-01"/><FilterOption count="1" label="1996-11-07"/><FilterOption count="1" label="1996-12-09"/><FilterOption count="1" label="1996-12-11"/><FilterOption count="1" label="1997-01-21"/><FilterOption count="1" label="1997-01-23"/><FilterOption count="1" label="1997-01-27"/><FilterOption count="1" label="1997-02-07"/><FilterOption count="1" label="1997-02-25"/><FilterOption count="1" label="1997-03-05"/><FilterOption count="1" label="1997-05-02"/><FilterOption count="1" label="1997-05-15"/><FilterOption count="1" label="1997-05-29"/><FilterOption count="1" label="1997-06-09"/><FilterOption count="1" label="1997-06-19"/><FilterOption count="1" label="1997-07-14"/><FilterOption count="1" label="1997-07-29"/><FilterOption count="1" label="1997-07-30"/><FilterOption count="1" label="1997-08-12"/><FilterOption count="1" label="1997-08-19"/><FilterOption count="1" label="1997-09-18"/><FilterOption count="1" label="1997-09-25"/><FilterOption count="1" label="1997-10-03"/><FilterOption count="1" label="1997-10-13"/><FilterOption count="1" label="1997-10-21"/><FilterOption count="1" label="1997-11-27"/></Filter><Filter label="Drug Has Financials" name="drugHasFinancials" total="2"><FilterOption count="726" label="No"/><FilterOption count="289" label="Yes"/></Filter><Filter label="Secondary Companies" name="companiesSecondary" total="100"><FilterOption id="18767" count="21" label="Pfizer Inc"/><FilterOption id="28355" count="18" label="GlaxoSmithKline plc"/><FilterOption id="14455" count="14" label="Bayer AG"/><FilterOption id="15065" count="13" label="Bristol-Myers Squibb Co"/><FilterOption id="24652" count="13" label="Shire plc"/><FilterOption id="13601" count="12" label="Abbott Laboratories"/><FilterOption id="18077" count="12" label="Merck &amp; Co Inc"/><FilterOption id="23137" count="12" label="Novartis AG"/><FilterOption id="17810" count="10" label="Eli Lilly &amp; Co"/><FilterOption id="15873" count="9" label="Elan Corp plc"/><FilterOption id="17332" count="9" label="Johnson &amp; Johnson"/><FilterOption id="19446" count="9" label="Roche Holding AG"/><FilterOption id="1009547" count="9" label="Sanofi SA"/><FilterOption id="1013295" count="8" label="Astellas Pharma Inc"/><FilterOption id="14190" count="8" label="AstraZeneca plc"/><FilterOption id="19862" count="8" label="Merck Serono SA"/><FilterOption id="16299" count="8" label="Sanofi Genzyme"/><FilterOption id="20300" count="8" label="Takeda Pharmaceutical Co Ltd"/><FilterOption id="19453" count="7" label="Genentech Inc"/><FilterOption id="21991" count="7" label="Takeda Oncology"/><FilterOption id="14109" count="6" label="Amgen Inc"/><FilterOption id="19687" count="6" label="Bayer Schering Pharma AG"/><FilterOption id="15414" count="6" label="Chugai Pharmaceutical Co Ltd"/><FilterOption id="21697" count="6" label="Cubist Pharmaceuticals Inc"/><FilterOption id="17259" count="6" label="Ipsen"/><FilterOption id="18101" count="6" label="Merck KGaA"/><FilterOption id="19711" count="6" label="Schering-Plough Corp"/><FilterOption id="23780" count="5" label="Actelion Ltd"/><FilterOption id="14437" count="5" label="Baxter International Inc"/><FilterOption id="15872" count="5" label="Eisai Co Ltd"/><FilterOption id="16453" count="5" label="Glaxo Group Ltd"/><FilterOption id="18717" count="5" label="Otsuka Pharmaceutical Co Ltd"/><FilterOption id="20611" count="5" label="University of Maryland"/><FilterOption id="18751" count="4" label="Acambis plc"/><FilterOption id="1109518" count="4" label="Baxalta Inc"/><FilterOption id="14695" count="4" label="BioCryst Pharmaceuticals Inc"/><FilterOption id="1005244" count="4" label="Biogen Inc"/><FilterOption id="25861" count="4" label="BioMarin Pharmaceutical Inc"/><FilterOption id="14881" count="4" label="Boehringer Ingelheim International GmbH"/><FilterOption id="26469" count="4" label="Genmab A/S"/><FilterOption id="16450" count="4" label="Gilead Sciences Inc"/><FilterOption id="17900" count="4" label="H Lundbeck A/S"/><FilterOption id="23382" count="4" label="MD Anderson Cancer Center"/><FilterOption id="17968" count="4" label="Medarex Inc"/><FilterOption id="20631" count="4" label="Mount Sinai School of Medicine"/><FilterOption id="20518" count="4" label="National Institutes of Health"/><FilterOption id="27477" count="4" label="Paladin Labs Inc"/><FilterOption id="29253" count="4" label="Pharmion Corp"/><FilterOption id="22127" count="4" label="Sanofi Pasteur"/><FilterOption id="20348" count="4" label="Teva Pharmaceutical Industries Ltd"/><FilterOption id="25451" count="4" label="University of California San Diego"/><FilterOption id="1009646" count="3" label="Acceleron Pharma Inc"/><FilterOption id="13765" count="3" label="Agennix AG"/><FilterOption id="13979" count="3" label="Alexion Pharmaceuticals Inc"/><FilterOption id="15623" count="3" label="ASTA Medica AG"/><FilterOption id="21885" count="3" label="Astex Pharmaceuticals Inc"/><FilterOption id="29750" count="3" label="Baxter Oncology GmbH"/><FilterOption id="18500" count="3" label="BELLUS Health Inc"/><FilterOption id="24236" count="3" label="Cambridge Antibody Technology Group plc"/><FilterOption id="14774" count="3" label="Cascadian Therapeutics Inc"/><FilterOption id="22534" count="3" label="Cystic Fibrosis Foundation Therapeutics Inc"/><FilterOption id="15585" count="3" label="CytRx Corp"/><FilterOption id="26178" count="3" label="F Hoffmann-La Roche AG"/><FilterOption id="20586" count="3" label="Hebrew University of Jerusalem"/><FilterOption id="17269" count="3" label="Ionis Pharmaceuticals Inc"/><FilterOption id="17724" count="3" label="Kyowa Hakko Kogyo Co Ltd"/><FilterOption id="27414" count="3" label="LeukoSite Inc"/><FilterOption id="18203" count="3" label="MGI Pharma Inc"/><FilterOption id="18676" count="3" label="OSI Pharmaceuticals Inc"/><FilterOption id="24232" count="3" label="Spectrum Pharmaceuticals Inc"/><FilterOption id="20679" count="3" label="Stanford University"/><FilterOption id="19143" count="3" label="The Procter &amp; Gamble Co"/><FilterOption id="24773" count="3" label="University of California San Francisco"/><FilterOption id="1072507" count="2" label="AbbVie Inc"/><FilterOption id="1091118" count="2" label="Abeona Therapeutics LLC"/><FilterOption id="1020514" count="2" label="Abraxis BioScience Inc"/><FilterOption id="20225" count="2" label="Achieve Life Sciences Inc"/><FilterOption id="24347" count="2" label="Acorda Therapeutics Inc"/><FilterOption id="22990" count="2" label="Aeolus Pharmaceuticals Inc"/><FilterOption id="29341" count="2" label="Affinium Pharmaceuticals Inc"/><FilterOption id="26488" count="2" label="Agouron Pharmaceuticals Inc"/><FilterOption id="24282" count="2" label="Albert Einstein College of Medicine"/><FilterOption id="14042" count="2" label="Allergan Inc"/><FilterOption id="28948" count="2" label="Anesiva Inc"/><FilterOption id="1075117" count="2" label="Antecip Bioventures II LLC"/><FilterOption id="17253" count="2" label="Ardea Biosciences Inc"/><FilterOption id="14296" count="2" label="ARIAD Pharmaceuticals Inc"/><FilterOption id="24948" count="2" label="Ark Therapeutics Group plc"/><FilterOption id="25218" count="2" label="Aventis Pharma AG"/><FilterOption id="27254" count="2" label="Aventis SA"/><FilterOption id="23133" count="2" label="Aviragen Therapeutics Inc"/><FilterOption id="1037227" count="2" label="BL&amp;H Co Ltd"/><FilterOption id="15331" count="2" label="Celgene Corp"/><FilterOption id="1022454" count="2" label="Cempra Inc"/><FilterOption id="15385" count="2" label="Chiron Corp"/><FilterOption id="29269" count="2" label="Corporate Technology Development Inc"/><FilterOption id="25491" count="2" label="CuraGen Corp"/><FilterOption id="1017506" count="2" label="Daiichi Sankyo Co Ltd"/><FilterOption id="1020322" count="2" label="Daiichi Sankyo Inc"/><FilterOption id="15593" count="2" label="Daiichi Seiyaku Co Ltd"/></Filter><Filter label="Primary Indications" name="indicationsPrimary" total="100"><FilterOption id="3657" count="42" label="Metastatic breast cancer"/><FilterOption id="1731" count="39" label="Acute myelogenous leukemia"/><FilterOption id="799" count="39" label="Ovary tumor"/><FilterOption id="1262" count="37" label="Non-small-cell lung cancer"/><FilterOption id="49" count="34" label="Breast tumor"/><FilterOption id="725" count="34" label="Solid tumor"/><FilterOption id="2454" count="31" label="Glioblastoma"/><FilterOption id="1272" count="29" label="Myelodysplastic syndrome"/><FilterOption id="3665" count="27" label="Metastatic non small cell lung cancer"/><FilterOption id="651" count="26" label="Cancer"/><FilterOption id="623" count="26" label="Head and neck tumor"/><FilterOption id="213" count="25" label="Multiple sclerosis"/><FilterOption id="40" count="24" label="Bacterial infection"/><FilterOption id="319" count="24" label="Non-Hodgkin lymphoma"/><FilterOption id="249" count="24" label="Pancreas tumor"/><FilterOption id="1815" count="23" label="Bacterial pneumonia"/><FilterOption id="989" count="22" label="Colorectal tumor"/><FilterOption id="20" count="22" label="Pain"/><FilterOption id="2380" count="21" label="Bladder cancer"/><FilterOption id="3246" count="21" label="Hormone refractory prostate cancer"/><FilterOption id="3658" count="21" label="Metastatic colorectal cancer"/><FilterOption id="1828" count="21" label="Multiple myeloma"/><FilterOption id="2637" count="21" label="Non-alcoholic steatohepatitis"/><FilterOption id="3713" count="20" label="Advanced solid tumor"/><FilterOption id="1766" count="20" label="Renal cell carcinoma"/><FilterOption id="485" count="19" label="Bacterial skin infection"/><FilterOption id="3257" count="19" label="Stage IV melanoma"/><FilterOption id="127" count="19" label="Stomach tumor"/><FilterOption id="14" count="18" label="Alzheimers disease"/><FilterOption id="1767" count="18" label="Hepatocellular carcinoma"/><FilterOption id="3669" count="18" label="Metastatic pancreas cancer"/><FilterOption id="4250" count="18" label="Metastatic renal cell carcinoma"/><FilterOption id="1261" count="18" label="Small-cell lung cancer"/><FilterOption id="1734" count="17" label="Chronic lymphocytic leukemia"/><FilterOption id="1108" count="17" label="Glioma"/><FilterOption id="616" count="17" label="Graft versus host disease"/><FilterOption id="212" count="16" label="Motor neurone disease"/><FilterOption id="1771" count="16" label="Transitional cell carcinoma"/><FilterOption id="88" count="15" label="Cystic fibrosis"/><FilterOption id="1749" count="15" label="Diffuse large B-cell lymphoma"/><FilterOption id="1705" count="15" label="Endometrioid carcinoma"/><FilterOption id="158" count="15" label="HIV infection"/><FilterOption id="1728" count="14" label="Acute lymphoblastic leukemia"/><FilterOption id="3898" count="14" label="Complicated urinary tract infection"/><FilterOption id="1745" count="14" label="Follicle center lymphoma"/><FilterOption id="203" count="14" label="Lymphoma"/><FilterOption id="307" count="14" label="Squamous cell carcinoma"/><FilterOption id="1011" count="13" label="Esophagus tumor"/><FilterOption id="3673" count="13" label="Metastatic head and neck cancer"/><FilterOption id="255" count="13" label="Parkinsons disease"/><FilterOption id="1753" count="13" label="Peripheral T-cell lymphoma"/><FilterOption id="55" count="12" label="Cardiac failure"/><FilterOption id="2020" count="12" label="Duchenne dystrophy"/><FilterOption id="2054" count="12" label="Hematological neoplasm"/><FilterOption id="205" count="12" label="Melanoma"/><FilterOption id="1240" count="12" label="Mesothelioma"/><FilterOption id="3466" count="12" label="Metastatic bladder cancer"/><FilterOption id="3666" count="12" label="Metastatic stomach cancer"/><FilterOption id="284" count="12" label="Pyelonephritis"/><FilterOption id="1754" count="11" label="Cutaneous T-cell lymphoma"/><FilterOption id="1128" count="11" label="Neuroendocrine tumor"/><FilterOption id="3083" count="11" label="Peritoneal tumor"/><FilterOption id="276" count="11" label="Prostate tumor"/><FilterOption id="291" count="11" label="Rheumatoid arthritis"/><FilterOption id="1516" count="10" label="Biliary cancer"/><FilterOption id="2243" count="10" label="Fallopian tube cancer"/><FilterOption id="3771" count="10" label="Idiopathic pulmonary fibrosis"/><FilterOption id="4898" count="10" label="Major depressive disorder"/><FilterOption id="2436" count="10" label="Myelofibrosis"/><FilterOption id="367" count="10" label="Radiation sickness"/><FilterOption id="31" count="9" label="Asthma"/><FilterOption id="423" count="9" label="Autism"/><FilterOption id="124" count="9" label="Fungal infection"/><FilterOption id="201" count="9" label="Liver disease"/><FilterOption id="1295" count="9" label="Neuropathic pain"/><FilterOption id="303" count="9" label="Sickle cell anemia"/><FilterOption id="3378" count="9" label="Soft tissue sarcoma"/><FilterOption id="308" count="9" label="Staphylococcus aureus infection"/><FilterOption id="318" count="9" label="Systemic lupus erythematosus"/><FilterOption id="311" count="9" label="T-cell lymphoma"/><FilterOption id="1185" count="8" label="Chronic obstructive pulmonary disease"/><FilterOption id="119" count="8" label="Epilepsy"/><FilterOption id="153" count="8" label="Hepatitis C virus infection"/><FilterOption id="161" count="8" label="Hodgkins disease"/><FilterOption id="1744" count="8" label="Mantle cell lymphoma"/><FilterOption id="3866" count="8" label="Metastatic ovary cancer"/><FilterOption id="3288" count="8" label="Non alcoholic fatty liver disease"/><FilterOption id="1772" count="8" label="Osteosarcoma"/><FilterOption id="1134" count="8" label="Thyroid tumor"/><FilterOption id="427" count="8" label="Uterine cervix tumor"/><FilterOption id="29" count="7" label="Aspergillus infection"/><FilterOption id="36" count="7" label="Autoimmune disease"/><FilterOption id="1765" count="7" label="Cholangiocarcinoma"/><FilterOption id="755" count="7" label="Lung tumor"/><FilterOption id="1267" count="7" label="MRSA infection"/><FilterOption id="65" count="7" label="Stroke"/><FilterOption id="1102" count="6" label="Atopic dermatitis"/><FilterOption id="1735" count="6" label="Chronic myelocytic leukemia"/><FilterOption id="156" count="6" label="Hereditary angioedema"/><FilterOption id="170" count="6" label="Huntingtons chorea"/></Filter><Filter label="Secondary Indications" name="indicationsSecondary" total="100"><FilterOption id="651" count="136" label="Cancer"/><FilterOption id="725" count="76" label="Solid tumor"/><FilterOption id="49" count="65" label="Breast tumor"/><FilterOption id="1262" count="49" label="Non-small-cell lung cancer"/><FilterOption id="799" count="48" label="Ovary tumor"/><FilterOption id="989" count="46" label="Colorectal tumor"/><FilterOption id="276" count="41" label="Prostate tumor"/><FilterOption id="249" count="38" label="Pancreas tumor"/><FilterOption id="205" count="36" label="Melanoma"/><FilterOption id="3246" count="30" label="Hormone refractory prostate cancer"/><FilterOption id="188" count="27" label="Inflammatory disease"/><FilterOption id="1828" count="27" label="Multiple myeloma"/><FilterOption id="40" count="25" label="Bacterial infection"/><FilterOption id="755" count="25" label="Lung tumor"/><FilterOption id="319" count="25" label="Non-Hodgkin lymphoma"/><FilterOption id="1734" count="23" label="Chronic lymphocytic leukemia"/><FilterOption id="1108" count="23" label="Glioma"/><FilterOption id="623" count="23" label="Head and neck tumor"/><FilterOption id="1261" count="20" label="Small-cell lung cancer"/><FilterOption id="65" count="20" label="Stroke"/><FilterOption id="1731" count="19" label="Acute myelogenous leukemia"/><FilterOption id="194" count="19" label="Sarcoma"/><FilterOption id="4250" count="18" label="Metastatic renal cell carcinoma"/><FilterOption id="2454" count="17" label="Glioblastoma"/><FilterOption id="291" count="17" label="Rheumatoid arthritis"/><FilterOption id="127" count="17" label="Stomach tumor"/><FilterOption id="14" count="16" label="Alzheimers disease"/><FilterOption id="199" count="16" label="Leukemia"/><FilterOption id="1272" count="16" label="Myelodysplastic syndrome"/><FilterOption id="281" count="16" label="Psoriasis"/><FilterOption id="3257" count="16" label="Stage IV melanoma"/><FilterOption id="31" count="15" label="Asthma"/><FilterOption id="36" count="15" label="Autoimmune disease"/><FilterOption id="2054" count="15" label="Hematological neoplasm"/><FilterOption id="153" count="15" label="Hepatitis C virus infection"/><FilterOption id="1767" count="15" label="Hepatocellular carcinoma"/><FilterOption id="1766" count="15" label="Renal cell carcinoma"/><FilterOption id="427" count="15" label="Uterine cervix tumor"/><FilterOption id="1226" count="14" label="Age related macular degeneration"/><FilterOption id="55" count="14" label="Cardiac failure"/><FilterOption id="88" count="14" label="Cystic fibrosis"/><FilterOption id="158" count="14" label="HIV infection"/><FilterOption id="3657" count="14" label="Metastatic breast cancer"/><FilterOption id="213" count="14" label="Multiple sclerosis"/><FilterOption id="239" count="14" label="Ocular disease"/><FilterOption id="760" count="13" label="Brain tumor"/><FilterOption id="1749" count="13" label="Diffuse large B-cell lymphoma"/><FilterOption id="20" count="13" label="Pain"/><FilterOption id="42" count="12" label="Bladder tumor"/><FilterOption id="84" count="12" label="Crohns disease"/><FilterOption id="202" count="12" label="Liver tumor"/><FilterOption id="1744" count="12" label="Mantle cell lymphoma"/><FilterOption id="57" count="11" label="Cardiovascular disease"/><FilterOption id="1735" count="11" label="Chronic myelocytic leukemia"/><FilterOption id="224" count="11" label="Myocardial infarction"/><FilterOption id="3713" count="10" label="Advanced solid tumor"/><FilterOption id="60" count="10" label="Central nervous system disease"/><FilterOption id="767" count="10" label="Colon tumor"/><FilterOption id="100" count="10" label="Diabetic nephropathy"/><FilterOption id="1011" count="10" label="Esophagus tumor"/><FilterOption id="203" count="10" label="Lymphoma"/><FilterOption id="3665" count="10" label="Metastatic non small cell lung cancer"/><FilterOption id="837" count="10" label="Non-insulin dependent diabetes"/><FilterOption id="255" count="10" label="Parkinsons disease"/><FilterOption id="299" count="10" label="Schizophrenia"/><FilterOption id="1143" count="9" label="Amyloidosis"/><FilterOption id="2380" count="9" label="Bladder cancer"/><FilterOption id="2659" count="9" label="Diabetic macular edema"/><FilterOption id="189" count="9" label="Inflammatory bowel disease"/><FilterOption id="212" count="9" label="Motor neurone disease"/><FilterOption id="1295" count="9" label="Neuropathic pain"/><FilterOption id="337" count="9" label="Ulcerative colitis"/><FilterOption id="344" count="9" label="Viral infection"/><FilterOption id="1745" count="8" label="Follicle center lymphoma"/><FilterOption id="616" count="8" label="Graft versus host disease"/><FilterOption id="836" count="8" label="Insulin dependent diabetes"/><FilterOption id="1240" count="8" label="Mesothelioma"/><FilterOption id="318" count="8" label="Systemic lupus erythematosus"/><FilterOption id="316" count="7" label="B-cell lymphoma"/><FilterOption id="131" count="7" label="Gastrointestinal tumor"/><FilterOption id="170" count="7" label="Huntingtons chorea"/><FilterOption id="3083" count="7" label="Peritoneal tumor"/><FilterOption id="515" count="7" label="Transplant rejection"/><FilterOption id="1107" count="6" label="Allergic rhinitis"/><FilterOption id="1815" count="6" label="Bacterial pneumonia"/><FilterOption id="1185" count="6" label="Chronic obstructive pulmonary disease"/><FilterOption id="995" count="6" label="Clostridium difficile infection"/><FilterOption id="353" count="6" label="Cognitive disorder"/><FilterOption id="1559" count="6" label="Congestive heart failure"/><FilterOption id="1754" count="6" label="Cutaneous T-cell lymphoma"/><FilterOption id="576" count="6" label="Diabetic retinopathy"/><FilterOption id="2020" count="6" label="Duchenne dystrophy"/><FilterOption id="124" count="6" label="Fungal infection"/><FilterOption id="584" count="6" label="Lipid metabolism disorder"/><FilterOption id="201" count="6" label="Liver disease"/><FilterOption id="655" count="6" label="Metabolic disorder"/><FilterOption id="3673" count="6" label="Metastatic head and neck cancer"/><FilterOption id="233" count="6" label="Neurodegenerative disease"/><FilterOption id="69" count="6" label="Renal failure"/><FilterOption id="999" count="6" label="Renal tumor"/></Filter><Filter label="Regulatory Designations" name="drugRegulatoryDesignations" total="18"><FilterOption id="2" count="1015" label="Fast Track"/><FilterOption id="1" count="585" label="Orphan Drug"/><FilterOption id="3" count="93" label="Breakthrough Therapy"/><FilterOption id="11" count="90" label="Priority Review"/><FilterOption id="9" count="86" label="Paediatric Investigation Plan"/><FilterOption id="12" count="75" label="Qualified Infectious Disease Product"/><FilterOption id="5" count="54" label="Accelerated Approval"/><FilterOption id="13" count="54" label="Rare Pediatric Disease"/><FilterOption id="10" count="22" label="PRIME"/><FilterOption id="16" count="21" label="Promising Innovative Medicine"/><FilterOption id="17" count="11" label="Regenerative Medicine Advanced Therapy"/><FilterOption id="14" count="10" label="Sakigake"/><FilterOption id="6" count="9" label="Animal Rule"/><FilterOption id="4" count="8" label="Advanced Therapy Medicinal Product"/><FilterOption id="7" count="6" label="Emergency Use Authorization"/><FilterOption id="19" count="4" label="Special Review Project"/><FilterOption id="8" count="2" label="New Active Substance"/><FilterOption id="15" count="1" label="Tropical Disease Priority Review"/></Filter><Filter label="Primary Actions" name="actionsPrimary" total="100"><FilterOption id="431" count="12" label="DNA gyrase inhibitor"/><FilterOption id="621" count="10" label="Amyloid protein deposition inhibitor"/><FilterOption id="740" count="10" label="Epidermal growth factor receptor antagonist"/><FilterOption id="3806" count="10" label="Flt3 tyrosine kinase inhibitor"/><FilterOption id="3808" count="10" label="Kit tyrosine kinase inhibitor"/><FilterOption id="142" count="10" label="Topoisomerase II inhibitor"/><FilterOption id="138" count="9" label="DNA polymerase inhibitor"/><FilterOption id="3191" count="9" label="Glucocorticoid receptor agonist"/><FilterOption id="86" count="8" label="Beta lactamase inhibitor"/><FilterOption id="948" count="8" label="PDGF receptor antagonist"/><FilterOption id="1722" count="8" label="VEGF receptor antagonist"/><FilterOption id="3848" count="8" label="VEGF-2 receptor antagonist"/><FilterOption id="3756" count="7" label="Erbb2 tyrosine kinase receptor inhibitor"/><FilterOption id="12358" count="7" label="Hepatitis C virus NS5B polymerase inhibitor"/><FilterOption id="281" count="7" label="NMDA receptor antagonist"/><FilterOption id="287" count="7" label="Opioid receptor agonist"/><FilterOption id="585" count="6" label="5-HT 2a receptor antagonist"/><FilterOption id="7343" count="6" label="Beta amyloid antagonist"/><FilterOption id="10232" count="6" label="CFTR modulator"/><FilterOption id="3564" count="6" label="Jak2 tyrosine kinase inhibitor"/><FilterOption id="288" count="6" label="Opioid receptor antagonist"/><FilterOption id="48492" count="6" label="PDGF receptor beta antagonist"/><FilterOption id="141" count="6" label="Topoisomerase I inhibitor"/><FilterOption id="3846" count="6" label="VEGF-1 receptor antagonist"/><FilterOption id="3850" count="6" label="VEGF-3 receptor antagonist"/><FilterOption id="61991" count="5" label="1,3 beta glucan synthase inhibitor"/><FilterOption id="60" count="5" label="Androgen receptor antagonist"/><FilterOption id="3107" count="5" label="CCR5 chemokine antagonist"/><FilterOption id="12349" count="5" label="Hepatitis C virus NS3 protease inhibitor"/><FilterOption id="3562" count="5" label="Jak1 tyrosine kinase inhibitor"/><FilterOption id="777" count="5" label="Lanosterol-14 demethylase inhibitor"/><FilterOption id="10240" count="5" label="mTOR inhibitor"/><FilterOption id="48489" count="5" label="PDGF receptor alpha antagonist"/><FilterOption id="347" count="5" label="RNA polymerase inhibitor"/><FilterOption id="143" count="5" label="Topoisomerase inhibitor"/><FilterOption id="2578" count="4" label="Cannabinoid CB2 receptor modulator"/><FilterOption id="10233" count="4" label="CFTR stimulator"/><FilterOption id="973" count="4" label="Complement cascade inhibitor"/><FilterOption id="7793" count="4" label="Ghrelin receptor agonist"/><FilterOption id="43842" count="4" label="Hepatitis C virus protein NS5A inhibitor"/><FilterOption id="1016" count="4" label="HIV-1 reverse transcriptase inhibitor"/><FilterOption id="1820" count="4" label="NMDA receptor modulator"/><FilterOption id="293" count="4" label="Opioid receptor mu agonist"/><FilterOption id="11183" count="4" label="Phosphoinositide-3 kinase delta inhibitor"/><FilterOption id="3816" count="4" label="RET tyrosine kinase receptor family inhibitor"/><FilterOption id="541" count="4" label="Tubulin receptor antagonist"/><FilterOption id="6937" count="4" label="Vanilloid VR1 agonist"/><FilterOption id="33500" count="3" label="30S ribosomal protein inhibitor"/><FilterOption id="33" count="3" label="Alpha 2 adrenoceptor agonist"/><FilterOption id="543" count="3" label="Amylase stimulator"/><FilterOption id="12791" count="3" label="Anthrax protective antigen inhibitor"/><FilterOption id="9305" count="3" label="Beta secretase 1 inhibitor"/><FilterOption id="2577" count="3" label="Cannabinoid CB1 receptor modulator"/><FilterOption id="150" count="3" label="Dopamine D2 receptor antagonist"/><FilterOption id="3755" count="3" label="Erbb2 tyrosine kinase receptor modulator"/><FilterOption id="168" count="3" label="FGF receptor antagonist"/><FilterOption id="3688" count="3" label="FGF3 receptor antagonist"/><FilterOption id="410" count="3" label="GM-CSF receptor agonist"/><FilterOption id="12479" count="3" label="Interleukin-1 beta ligand inhibitor"/><FilterOption id="1832" count="3" label="Nucleoside reverse transcriptase inhibitor"/><FilterOption id="2507" count="3" label="PARP inhibitor"/><FilterOption id="304" count="3" label="PDE 4 inhibitor"/><FilterOption id="1575" count="3" label="Phosphoinositide 3-kinase inhibitor"/><FilterOption id="377" count="3" label="TGF beta receptor antagonist"/><FilterOption id="814" count="3" label="Tubulin modulator"/><FilterOption id="11842" count="2" label="5-HT 1a receptor partial agonist"/><FilterOption id="1846" count="2" label="5-HT 2a receptor modulator"/><FilterOption id="440" count="2" label="5-HT 4 receptor agonist"/><FilterOption id="1924" count="2" label="5-HT 6 receptor antagonist"/><FilterOption id="247" count="2" label="5-Lipoxygenase inhibitor"/><FilterOption id="28" count="2" label="Adrenergic receptor agonist"/><FilterOption id="34052" count="2" label="Adrenocorticotrophic hormone ligand"/><FilterOption id="3859" count="2" label="AKT protein kinase inhibitor"/><FilterOption id="7580" count="2" label="Alkaline phosphatase stimulator"/><FilterOption id="34" count="2" label="Alpha 2 adrenoceptor antagonist"/><FilterOption id="6927" count="2" label="Alpha 2C adrenoceptor antagonist"/><FilterOption id="29" count="2" label="Alpha adrenoceptor agonist"/><FilterOption id="69441" count="2" label="Alpha N acetylglucosaminidase stimulator"/><FilterOption id="7147" count="2" label="Alpha-galactosidase stimulator"/><FilterOption id="18441" count="2" label="Alpha-L-iduronidase stimulator"/><FilterOption id="12788" count="2" label="Anthrax toxin inhibitor"/><FilterOption id="8255" count="2" label="APRIL receptor modulator"/><FilterOption id="517" count="2" label="Asparaginase stimulator"/><FilterOption id="3742" count="2" label="Axl tyrosine kinase receptor inhibitor"/><FilterOption id="5083" count="2" label="B-lymphocyte antigen CD20 modulator"/><FilterOption id="81" count="2" label="Benzodiazepine receptor agonist"/><FilterOption id="789" count="2" label="Bradykinin B2 receptor antagonist"/><FilterOption id="4010" count="2" label="Calcineurin inhibitor"/><FilterOption id="93" count="2" label="Calcium channel inhibitor"/><FilterOption id="2603" count="2" label="Caspase inhibitor"/><FilterOption id="3098" count="2" label="CCR2 chemokine antagonist"/><FilterOption id="5023" count="2" label="CD3 modulator"/><FilterOption id="5028" count="2" label="CD4 antagonist"/><FilterOption id="38488" count="2" label="CNGB3 gene stimulator"/><FilterOption id="3728" count="2" label="CNTF receptor agonist"/><FilterOption id="15172" count="2" label="Complement C1s subcomponent inhibitor"/><FilterOption id="15127" count="2" label="Complement C3 inhibitor"/><FilterOption id="3154" count="2" label="CSF-1 antagonist"/><FilterOption id="416" count="2" label="Cytochrome P450 reductase inhibitor"/><FilterOption id="6515" count="2" label="Cytosine DNA methyltransferase inhibitor"/></Filter><Filter label="Primary Companies" name="companiesPrimary" total="100"><FilterOption id="18767" count="19" label="Pfizer Inc"/><FilterOption id="18077" count="15" label="Merck &amp; Co Inc"/><FilterOption id="23137" count="15" label="Novartis AG"/><FilterOption id="15331" count="10" label="Celgene Corp"/><FilterOption id="24652" count="10" label="Shire plc"/><FilterOption id="1013295" count="8" label="Astellas Pharma Inc"/><FilterOption id="16450" count="8" label="Gilead Sciences Inc"/><FilterOption id="18008" count="8" label="MedImmune LLC"/><FilterOption id="18681" count="8" label="Ono Pharmaceutical Co Ltd"/><FilterOption id="1009547" count="8" label="Sanofi SA"/><FilterOption id="20300" count="8" label="Takeda Pharmaceutical Co Ltd"/><FilterOption id="14109" count="7" label="Amgen Inc"/><FilterOption id="14190" count="7" label="AstraZeneca plc"/><FilterOption id="14455" count="7" label="Bayer AG"/><FilterOption id="1005244" count="7" label="Biogen Inc"/><FilterOption id="1035060" count="7" label="Mitsubishi Tanabe Pharma Corp"/><FilterOption id="16299" count="7" label="Sanofi Genzyme"/><FilterOption id="19898" count="7" label="Shionogi &amp; Co Ltd"/><FilterOption id="1088700" count="6" label="Allergan plc"/><FilterOption id="1063950" count="6" label="Biotoscana International"/><FilterOption id="28355" count="6" label="GlaxoSmithKline plc"/><FilterOption id="18552" count="6" label="Nippon Shinyaku Co Ltd"/><FilterOption id="28921" count="6" label="Swedish Orphan Biovitrum AB"/><FilterOption id="20348" count="6" label="Teva Pharmaceutical Industries Ltd"/><FilterOption id="20739" count="6" label="Vertex Pharmaceuticals Inc"/><FilterOption id="15414" count="5" label="Chugai Pharmaceutical Co Ltd"/><FilterOption id="15872" count="5" label="Eisai Co Ltd"/><FilterOption id="17810" count="5" label="Eli Lilly &amp; Co"/><FilterOption id="1011990" count="5" label="Emergent BioSolutions Inc"/><FilterOption id="17332" count="5" label="Johnson &amp; Johnson"/><FilterOption id="1023179" count="5" label="Lee's Pharmaceutical Holdings Limited"/><FilterOption id="1085756" count="5" label="Mallinckrodt plc"/><FilterOption id="1059001" count="5" label="R-Pharm"/><FilterOption id="19446" count="5" label="Roche Holding AG"/><FilterOption id="19863" count="5" label="Servier"/><FilterOption id="17207" count="5" label="Soligenix Inc"/><FilterOption id="1062138" count="5" label="Ultragenyx Pharmaceutical Inc"/><FilterOption id="1072507" count="4" label="AbbVie Inc"/><FilterOption id="1179286" count="4" label="Acrotech Biopharma LLC"/><FilterOption id="13979" count="4" label="Alexion Pharmaceuticals Inc"/><FilterOption id="1063251" count="4" label="BeiGene Co Ltd"/><FilterOption id="15065" count="4" label="Bristol-Myers Squibb Co"/><FilterOption id="1022379" count="4" label="Hikma Pharmaceuticals plc"/><FilterOption id="17259" count="4" label="Ipsen"/><FilterOption id="26997" count="4" label="Janssen Biotech Inc"/><FilterOption id="1093663" count="4" label="Knight Therapeutics Inc"/><FilterOption id="1108651" count="4" label="MeiraGTx"/><FilterOption id="1045514" count="4" label="Mundipharma International Corp Ltd"/><FilterOption id="21388" count="4" label="Neopharm Ltd"/><FilterOption id="18717" count="4" label="Otsuka Pharmaceutical Co Ltd"/><FilterOption id="1041745" count="4" label="Proteostasis Therapeutics Inc"/><FilterOption id="1044298" count="4" label="Specialised Therapeutics Australia Pty Ltd"/><FilterOption id="1017117" count="4" label="Sumitomo Dainippon Pharma Co Ltd"/><FilterOption id="20452" count="4" label="UCB SA"/><FilterOption id="1101935" count="4" label="Zai Lab Limited"/><FilterOption id="22881" count="3" label="Abeona Therapeutics Inc"/><FilterOption id="13726" count="3" label="AMAG Pharmaceuticals Inc"/><FilterOption id="1033496" count="3" label="Aridis Pharmaceuticals Inc"/><FilterOption id="1149364" count="3" label="Avir Pharma Inc"/><FilterOption id="28104" count="3" label="Basilea Pharmaceutica International Ltd"/><FilterOption id="14881" count="3" label="Boehringer Ingelheim International GmbH"/><FilterOption id="15381" count="3" label="Chiesi Farmaceutici SpA"/><FilterOption id="1037068" count="3" label="China Medical System Holdings Ltd"/><FilterOption id="15620" count="3" label="Debiopharm SA"/><FilterOption id="29387" count="3" label="Dr Reddy's Laboratories Ltd"/><FilterOption id="1056888" count="3" label="Eddingpharm Inc"/><FilterOption id="1042566" count="3" label="Eurofarma"/><FilterOption id="1157539" count="3" label="Everest Medicines"/><FilterOption id="16583" count="3" label="GC Pharma"/><FilterOption id="19453" count="3" label="Genentech Inc"/><FilterOption id="17900" count="3" label="H Lundbeck A/S"/><FilterOption id="25863" count="3" label="Janssen Pharmaceuticals Inc"/><FilterOption id="17392" count="3" label="Janssen-Cilag Ltd"/><FilterOption id="1007377" count="3" label="Jazz Pharmaceuticals plc"/><FilterOption id="1042596" count="3" label="Kyowa Hakko Kirin Co Ltd"/><FilterOption id="28088" count="3" label="MediciNova Inc"/><FilterOption id="29943" count="3" label="Medison Pharma Ltd"/><FilterOption id="26786" count="3" label="MegaPharm Ltd"/><FilterOption id="19862" count="3" label="Merck Serono SA"/><FilterOption id="1033227" count="3" label="MicuRx Pharmaceuticals Inc"/><FilterOption id="19214" count="3" label="Regeneron Pharmaceuticals Inc"/><FilterOption id="25162" count="3" label="Sangamo Therapeutics Inc"/><FilterOption id="22730" count="3" label="Servier Canada Inc"/><FilterOption id="20436" count="3" label="Shire Human Genetic Therapies Inc"/><FilterOption id="1154395" count="3" label="SpringWorks Therapeutics Inc"/><FilterOption id="20984" count="3" label="Yuhan Corp"/><FilterOption id="1016672" count="2" label="3SBio Inc"/><FilterOption id="31338" count="2" label="Ablynx NV"/><FilterOption id="1010882" count="2" label="Acer Therapeutics Inc"/><FilterOption id="1111343" count="2" label="Adlai Nortye Pharmaceutical Co Ltd"/><FilterOption id="1040627" count="2" label="Agios Pharmaceuticals Inc"/><FilterOption id="1153354" count="2" label="Alfasigma SpA"/><FilterOption id="28514" count="2" label="AnGes MG Inc"/><FilterOption id="1008173" count="2" label="AOP Orphan Pharmaceuticals AG"/><FilterOption id="1063900" count="2" label="Apellis Pharmaceuticals Inc"/><FilterOption id="1113878" count="2" label="Aptinyx Inc"/><FilterOption id="1005640" count="2" label="ARCA Biopharma Inc"/><FilterOption id="14303" count="2" label="Asahi Kasei Pharma Corp"/><FilterOption id="1015044" count="2" label="Auris Medical Holding AG"/><FilterOption id="25861" count="2" label="BioMarin Pharmaceutical Inc"/></Filter><Filter label="Highest Phase" name="phaseHighest" total="12"><FilterOption id="L" count="255" label="Launched"/><FilterOption id="C2" count="237" label="Phase 2 Clinical"/><FilterOption id="C3" count="174" label="Phase 3 Clinical"/><FilterOption id="DX" count="168" label="Discontinued"/><FilterOption id="C1" count="48" label="Phase 1 Clinical"/><FilterOption id="PR" count="38" label="Pre-registration"/><FilterOption id="NDR" count="35" label="No Development Reported"/><FilterOption id="DR" count="33" label="Discovery"/><FilterOption id="R" count="11" label="Registered"/><FilterOption id="S" count="8" label="Suspended"/><FilterOption id="W" count="4" label="Withdrawn"/><FilterOption id="CU" count="4" label="Clinical"/></Filter></Filters></drugResultsOutput>